c-myc和CD24在结直肠癌的表达及意义

doi:10.3760/cma.j.issn.1673-422X.2015.04.005

摘要/Abstract

摘要： 目的检测cmyc和CD24在结直肠癌、息肉及正常黏膜中的表达，探讨c-myc和CD24在结直肠癌发生中的作用以及二者之间的关系。方法采用免疫组织化学法对60例结直肠癌、45例大肠腺瘤性息肉、15例大肠增生性息肉、30例正常结直肠黏膜石蜡切片进行cmyc和CD24表达的检测。结果cmyc阳性表达率在结直肠癌中为73.3%，明显高于大肠腺瘤性息肉44.4%（χ2=9.016 8，P＜0.01）、大肠增生性息肉13.3%（χ2=18.215 9，P＜0.01）和正常黏膜组织6.7%（χ2=35.573 1，P＜0.01）；CD24阳性表达率在结直肠癌中为76.7%，明显高于大肠增生性息肉6.7%（χ2=25.133 0，P＜0.01）、正常黏膜组织3.3%（χ2=43.107 4，P＜0.01）。cmyc与结直肠癌的肿瘤部位（χ2=8.352 3, P＜0.01）、淋巴结转移（χ2=4.275 1, P＜0.05）、分化程度（χ2=4.115 3, P＜0.05）和分期（χ2=5.739 9, P＜0.05）有相关性；CD24与肿瘤大小（χ2=9.333 6，P＜0.01）、淋巴结转移（χ2=7.693 0，P＜0.01）、分化程度（χ2=5.870 0, P＜0.05）和分期（χ2=4.498 7, P＜0.05）有相关性。结直肠癌组织中CD24与cmyc 表达呈正相关（χ2=10.824 9，r=0.39,P＜0.05）。结论cmyc与CD24在结直肠癌中高表达，且与一些临床病理特征有关。在结直肠癌的发生、进展、转移过程中，cmyc很可能充当了CD24信号通路的下游靶基因，受CD24调控。

关键词: 结直肠肿瘤, 免疫组织化学, 基因, myc, CD24

Abstract: 【Abstract】ObjectiveTo determine the expression of cmyc and CD24 in colorectal carcinoma, colorectal polyp and normal mucosa, and to explore the role and correlation of them in the carcinogenesis of colorectal carcinoma. MethodsThe expression of cmyc and CD24 in colorectal carcinoma (n=60), colorectal adenomatous polyp (n=45), colorectal hyperplastic polyp (n=15) and the adjacent noncancerous tissue (n=30) was observed by immunohistochemical assay. ResultsThe positive rate of cmyc in colorectal carcinoma were 73.3%, significantly higher than that in colorectal adenomatous polyp 44.4% (χ2=9.016 8, P＜0.01), colorectal hyperplastic polyp 13.3% (χ2=18.215 9, P＜0.01) and adjacent noncancerous tissue 6.7% (χ2=25.133 0, P＜0.01); the positive rate of CD24 in colorectal carcinoma was 76.7%, significantly higher than that in colorectal hyperplastic polyp 6.7% (χ2=25.133 0, P＜0.01) and adjacent noncancerous tissue 3.3% (χ2=43.107 4, P＜0.01). cmyc expression in colon cancer was significantly correlated with cancer site (χ2=8.352 3, P＜0.01), lymph node metastasis (χ2=4.275 1, P＜0.05), differentiation (χ2=4.115 3, P＜0.05) and TNM stage (χ2=5.739 9, P＜0.05). CD24 expression in colon cancer was significantly correlated with cancer size (χ2=9.333 6, P＜0.01), lymph node metastasis (χ2=7.693 0, P＜0.01), differentiation (χ2=5.870 0, P＜0.05) and TNM stage (χ2=4.498 7, P＜0.05). There was a positive correlation relationship between CD24 and cmyc in colorectal carcinoma tissue (χ2=10.824 9, r=0.39, P＜0.05).ConclusionThe expression of cmyc and CD24 are high in colorectal cancer, having a significant correlation with some of the clinicaopathological features. cmyc is likely to act as a downstream target gene of CD24 signaling pathway, whose expression is probably regulated by CD24 in colorectal carcinoma tissue.

Key words: Colorectal neoplasms, Immunohistochemistry, Genes, myc, CD24

陈文军, 董崇海, 田字彬. c-myc和CD24在结直肠癌的表达及意义[J]. 国际肿瘤学杂志, 2015, 42(4): 255-258.

CHEN Wen-Jun, DONG Chong-Hai, TIAN Zi-Bin. Expression and significance of c-myc and CD24 in colorectal cancer[J]. Journal of International Oncology, 2015, 42(4): 255-258.

参考文献

［1］ Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer［J］. J Cell Physiol, 1999, 180(1): 1018. ［2］ Sagawa Y, Nishi H, Isaka K, et a1. The correlation of TERT expression with cmyc expression in cervical cancer［J］. Cancer Lett, 2001, 168(1): 4550. ［3］王伟飞, 王新颖, 岳辉, 等. CD24在大肠癌组织中的表达及其对癌细胞增殖的影响［J］. 实用癌症杂志, 2011, 26(1): 3741. ［4］ Tollefshol TO, Andrews LG. Mechanisms for telomerase gene control in aging cells and tumorigenesis［J］. Med Hypotheses, 2001, 56(6): 630637. ［5］ Baudino TA, McKay C, PendevilleSamain H, et al. cmyc is essential for vasculogenesis and angiogenesis during development and tumor progression［J］. Genes Dev, 2002, 16(19): 25302533. ［6］ Smith SC, Oxford G, Wu Z, et al. The metastasisassociated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer［J］. Cancer Res, 2006, 66(4): 19171922. ［7］ Aigner S, Sthoeger ZM, Fogel M, et al. CD24, a mucintype glycoprotein is a ligand for Pselection on human tumor cells［J］. Blood, 1997, 89(9): 33853395. ［8］刘剑仑, 葛莲英, 张贵年. p53、cmyc、PCNA在大肠癌过度表达的临床意义［J］. 大肠肛门病外科杂志, 2004, 10(1): 2123. ［9］ Sagiv E, Memeo L, Karin A, et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis［J］.Gastroenteroloty, 2006, 131(2): 630639. ［10］李超, 许芝林, 赵峥, 等. Kras基因与cmyc基因在大肠癌中的表达及相关性研究［J］. 哈尔滨医科大学学报, 2009, 43(6): 572575. ［11］ Weichert W, Denkert C, Burkhardt M, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival［J］. Clin Cancer Res, 2005, 11(18): 65746581. ［12］ He TC, Sparks AB, Rago C, et al. Identifition of cmyc as target of the APC pathway［J］. Science, 1998, 281(5382): 15091512.

[1]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[6]	吴佳丽, 张佳慧, 张萍, 肖昕悦, 李睿, 张红宇. Bcl-2 BH4选择性抑制剂BDA-366抑制NK/T细胞淋巴瘤细胞的机制研究[J]. 国际肿瘤学杂志, 2023, 50(7): 413-418.
[7]	李彬, 张桂芳, 周林静, 杨小冬, 何秋立, 贾思思, 黄普超, 梁嘉欣. 三阴性乳腺癌中PIK3CA基因状态与临床特征及预后的关系[J]. 国际肿瘤学杂志, 2023, 50(5): 263-267.
[8]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[9]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[10]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺. 结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[11]	徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[12]	廖利华, 王少洪, 陈洪才, 赵勇强. 细胞蜡块免疫组织化学与胸腔积液CRKL、MIC-1诊断恶性胸腔积液的价值[J]. 国际肿瘤学杂志, 2023, 50(2): 71-75.
[13]	刘玉杰, 赵志强, 王子琤. 早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[14]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[15]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.